News
Africa, Weight loss and Food and Drug Administration
Digest more
Bizcommunity on MSN6d
Danish weight-loss drug Wegovy debuts in South Africa, challenging Eli Lilly
Danish drugmaker Novo Nordisk introduced its weight-loss drug Wegovy in South Africa, marking its debut in Africa and ...
As of May 22, manufacturers are no longer allowed to distribute the compounded versions of semaglutide, which Novo Nordisk sells under the brand Wegovy for weight loss and Ozempic for diabetes.
Patients taking the GLP-1 weight loss drug Zepbound face mandatory switch to Wegovy after CVS Caremark removed the Eli Lilly medication from its preferred coverage list, citing rising costs.
The 50-year-old is now on Novo Nordisk ’s Wegovy, but worries because it is less effective. Studies have shown Wegovy helps people lose less weight, on average, than Zepbound.
Wegovy can cost upward of $349 for a 2.5-milligram vial. Meanwhile, Noom’s compounded semaglutide, offered through a telehealth model, allows patients to access the treatment at a fraction of ...
Campbell gained access to Wegovy through South Carolina Medicaid's decision in late 2024 to cover these weight loss drugs. But the medications remain out of reach for millions of patients across ...
Some consumers are taking smaller than standard doses of GLP-1s—the popular class of weight-loss and diabetes drugs that include Ozempic, Wegovy, and Zepbound—or spacing out doses longer than ...
While the 10-fold increase in dose over injectable Wegovy has raised questions about the launch, Novo Nordisk has assured ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback